مباشر
FierceBiotechClinical-stage cancer biotech Treeline sees path to public markets via reverse mergerFierceBiotechADA: Dexcom CGM shows benefit in non-insulin diabetes patientsEndpoints NewsTreeline to go public via reverse merger with Standard BioToolsFierceBiotechResmed snaps up Noctrix Health in $340M sleep tech dealBioWorldBiggest gainers and losers for June 1-5, 2026Endpoints NewsJ&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS fieldFierceBiotechJ&J makes $1B upfront bet on emerging DAC space by netting Firefly BioEndpoints NewsGSK inks multi-target pact with Engitix; Sangamo considers strategic optionsEndpoints NewsTango plans Phase 3 pancreatic cancer study after combo successEndpoints NewsComing SoonEndpoints NewsBiopharma's top-paid CEOs of 2025: 25 making $25M+Endpoints NewsCavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs
BioWorld ٣٠ ديسمبر ٢٠٢٥

2025 marks a breakthrough year for in vivo gene therapies

2025 marks a breakthrough year for in vivo gene therapies

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.